GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Revenue

InflaRx NV (InflaRx NV) Revenue : $0.07 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Revenue?

InflaRx NV's revenue for the three months ended in Dec. 2023 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07 Mil. InflaRx NV's Revenue per Share for the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


InflaRx NV Revenue Historical Data

The historical data trend for InflaRx NV's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Revenue Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only - - - - 0.07

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.07 -

Competitive Comparison of InflaRx NV's Revenue

For the Biotechnology subindustry, InflaRx NV's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Revenue distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Revenue falls into.



InflaRx NV Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV  (NAS:IFRX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


InflaRx NV Revenue Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (InflaRx NV) Headlines

From GuruFocus

InflaRx to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-06-2022